Novan has announced the reshaping of their executive team, to strengthen its clinical operations infrastructure and streamline research and development. Paula Brown Stafford will serve in the newly created position of chief development officer; she will team with Joyce, Rico, M.D., C.M.O. as Novan prepares for upcoming meetings with the FDA. Stanley Hollenbach has been promoted to senior vice president of research and development, broadening his responsibilities to include leadership over all phases of drug development other than clinical. William L. Hodges has been appointed interim chief financial officer, following the departure of
Richard Peterson.